Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoseFlex: Certolizumab Pegol in RA
NCT00580840Phase 4Completed
- Sponsor
- UCB
- Start
- Dec 2007
- Primary completion
- Dec 2010
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
A Phase 4 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Started Dec 2007; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00580840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00580840.